Renale Denervierung

详细信息    查看全文

• 作者：Dr. K. Kara (1)
  H. Bruck (2)
  P. Kahlert (1)
  B. Plicht (1)
  A.A. Mahabadi (1)
  T. Konorza (1)
  R. Erbel (1)
  
• 关键词：Therapierefrakt?re arterielle Hypertonie ; Sympathikusaktivit?t ; Renale Denervierung ; Renale Ablationstherapie ; Hochfrequenzablation ; Resistent hypertension ; Sympathetic activity ; Renal denervation ; Renal ablation ; Radiofrequency ablation
• 刊名：Herz
• 出版年：2012
• 出版时间：November 2012
• 年：2012
• 卷：37
• 期：7
• 页码：746-753
• 全文大小：611KB
• 参考文献：1. Erbel R, Lehmann N, M?hlenkamp S et al (2012) Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the Heinz Nixdorf Recall Study. Hypertension 59:44-3 CrossRef
  2. L?wel H, Meisinger C, Heier M et al (2006) Epidemiologie der arteriellen Hypertonie in Deutschland. Dtsch Med Wochenschr 131:2586-591 CrossRef
  3. Wolf-Maier K, Cooper RS, Kramer H et al (2004) Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43:10-7 CrossRef
  4. Calhoun DA, Jones D, Textor S et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:510-26 CrossRef
  5. Persell SD (2011) Prevalence of resistant hypertension in the United States, 2003-008. Hypertension 57:1076-80 CrossRef
  6. Sierra A de la, Segura J, Banegas JR et al (2011) Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57:898-02 CrossRef
  7. DiBona GFS (2002) Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 11:197-00 CrossRef
  8. Deutsche Hochdruckliga e.?V. -DHL (2009) Leitlinien zur Behandlung der arteriellen Hypertonie. Nieren- und Hochdruckkrankheiten 38:137-88
  9. Mahfoud F, Vonend O, Bruck H et al (2011) Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch Med Wochenschr 136:2418-424 CrossRef
  10. Goldstein DS (1983) Plasma catecholamines and essential hypertension: an analytical review. Hypertension 5:86-9 CrossRef
  11. Smith PA, Graham LN, Mackintosh AF et al (2004) Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 17:217-22 CrossRef
  12. Grimson KS (1941) Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg 114:753-75
  13. Peet M, Woods W, Braden S (1940) The surgical treatment of hypertension: results in 350 consecutive cases treated by bilateral supradiaphragmatic splanchnicectomy and lower dorsal sympathetic gangliectomy. Clinical lecture at New York session. JAMA 115:1875-885 CrossRef
  14. Smithwick RH (1948) Surgery in hypertension. Lancet 2:65
  15. Grimson KS, Orgain ES, Anderson B et al (1949) Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg 129:850-71 CrossRef
  16. Whitelaw GP, Kinsey D, Smithwick RH (1964) Factors influencing the choice of treatment in essential hypertension: surgical, medical, or a combination of both. Am J Surg 107:220-31 CrossRef
  17. Converse RL Jr, Jacobsen TN, Toto RD et al (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-918 CrossRef
  18. Hausberg M, Kosch M, Harmelink P et al (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-979 CrossRef
  19. Osborn JL, Holdaas H, Thames MD, DiBona GF (1983) Renal adrenoceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog. Circ Res 53:298-05 CrossRef
  20. Hopf HB, Schlaghecke R, Peters J (1994) Sympathetic neural blockade by thoracic epidural anesthesia suppresses renin release in response to arterial hypotension. Anesthesiology 80:992-99 CrossRef
  21. Ye S, Zhong H, Yanamadala V, Campese VM (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15:717-24 CrossRef
  22. Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275-281 CrossRef
  23. Schlaich MP, Sobotka PA, Krum H et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932-34 CrossRef
  24. Symplicity HTN-1 Investigators (2011) Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57:911-17 CrossRef
  25. Ganguly A (1998) Primary aldosteronism. N Engl J Med 339:1828-834 CrossRef
  26. Kaplan NM (2001) Cautions over the current epidemic of primary aldosteronism. Lancet 357:953-54 CrossRef
  27. Ukena C, Mahfoud F, Kindermann I et al (2011) Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 58:1176-182 CrossRef
  28. Redfield MM, Jacobsen SJ, Burnett JC Jr et al (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194-02 CrossRef
  29. Bombelli M, Facchetti R, Carugo S et al (2009) Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of office blood pressure values. J Hypertens 27:2458-464 CrossRef
  30. Okin PM, Devereux RB, Jern S et al (2004) Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292:2343-349 CrossRef
  31. De Caterina AR, Leone AM (2010) Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol 105:1433-438 CrossRef
  32. Di Bona GF (2005) Physiology in perspective: the wisdom of the body: neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289:633-41 CrossRef
  33. Vollenweider P, Tappy L, Randin D et al (1993) Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 92:147-54 CrossRef
  34. Huggett RJ, Scott EM, Gilbey SG, Stoker JB (2003) Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108:3097-101 CrossRef
  35. Julius S, Gudbrandsson T, Jamerson K et al (1991) The hemodynamic link between insulin resistance and hypertension. J Hypertens 9:983-86 CrossRef
  36. Koistinen HA, Zierath JR (2002) Regulation of glucose transport in human skeletal muscle. Ann Med 34:410-18 CrossRef
  37. Mancia G, Bousquet P, Elghozi JL et al (2007) The sympathetic nervous system and the metabolic syndrome. J Hypertens 25:909-20 CrossRef
  38. Julius S, Gudbrandsson T, Jamerson K (1992) The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Press 1:9-9 CrossRef
  39. Mahfoud F, Schlaich M, Kindermann I et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123:1940-946 CrossRef
  40. Witkowski A, Prejbisz A, Florczak E et al (2011) Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58:559-65 CrossRef
  41. Ukena C, Bauer A, Mahfoud F et al (2012) Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 101:63-7 CrossRef
  42. Cohn JN, Levine TB, Olivari MT (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-23 CrossRef
  43. Foody JM, Farrell MH, Krumholz HM (2002) Beta-blocker therapy in heart failure: scientific review. JAMA 287:883-89 CrossRef
  44. Johansson M, Elam M, Rundqvist B et al (1999) Increased sympathetic nerve activity in renovascular hypertension. Circulation 99:2537-542 CrossRef
  45. Rafiq K, Noma T, Fujisawa Y et al (2012) Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125:1402-413 CrossRef
  46. Esler M, Dudley F, Jennings G, Debinski H (1992) Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med 116:446-55
  47. Esler MD, Krum H, Sobotka PA et al (2010) Renal sympathetic denervation in patients with treatment resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376:1903-909 CrossRef
  
• 作者单位：Dr. K. Kara (1)
  H. Bruck (2)
  P. Kahlert (1)
  B. Plicht (1)
  A.A. Mahabadi (1)
  T. Konorza (1)
  R. Erbel (1)
  
  1. Klinik für Kardiologie, Westdeutsches Herzzentrum, Universit?tsklinikum Essen, Universit?t Essen-Duisburg, Hufelandstr. 55, 45147, Essen, Deutschland
  2. Klinik für Nephrologie, Universit?tsklinikum Essen, Universit?t Essen-Duisburg, Essen, Deutschland
  
• ISSN：1615-6692

文摘

Hypertension is a well-known risk factor for major cardiovascular events. Despite advances in medical therapy, sufficient treatment of hypertension remains unsatisfying in a substantial number of patients and is therefore one of the main challenges in modern medicine. In Germany 5-5?% of patients with hypertension suffer from resistant hypertension with elevated blood pressure despite the use of at least three antihypertensive drugs. Additionally patients often suffer from side effects. In patients with resistant hypertension the important role of the sympathetic nervous system with increased sympathetic activity is well known. In the past surgical sympathectomy with extended removal of sympathetic ganglia was performed to reduce blood pressure in patients with malignant hypertension. The positive effect of this highly invasive procedure on blood pressure led to the development of new strategies for the treatment of uncontrolled hypertension. One of the novel procedures includes catheter-based renal sympathetic denervation. The most common system is the radiofrequency ablation catheter (Symplicity?, Medtronic, Minneapolis, USA) which ablates the nerve fibers in the adventitia of the renal arteries by using high-frequency energy. As the results of the Symplicity trials (HTN-1 and HTN-2) showed significant reduction of systolic and diastolic blood pressure after renal denervation there is growing interest in this novel procedure. Moreover, by reducing the sympathetic activity after renal denervation early results indicate a positive impact on glucose metabolism, sleep apnea syndrome, as well as heart and renal failure. These effects led to the development of many different devices for renal denervation; however, trials with a higher number of patients and longer follow-up need to confirm these initially promising results and the value of newer devices. Until then renal denervation should not be regarded as standard therapy for arterial hypertension or an alternative to medical antihypertensive treatment and should be reserved for selected patients with resistant hypertension and specialized medical centres.